Weight-loss injections may help some women with polycystic ovary syndrome (PCOS) manage excess weight and associated metabolic complications. However, experts caution that these medicines do not cure the underlying hormonal condition and should never be used without medical supervision. With glucagon-like peptide-1 (GLP-1) receptor agonists gaining popularity for weight management, specialists have emphasised the need for individualised treatment plans. Such plans should consider a woman’s symptoms, body weight, metabolic health and reproductive goals rather than focus solely on weight reduction.
Weight-Loss Injections Do Not Treat All PCOS Symptoms
Dr Hrishikesh Pai, Gynaecologist and IVF Specialist and Medical Director of Bloom IVF Group, said weight-loss injections should not be considered a universal treatment for PCOS. The condition can cause irregular menstrual cycles, excessive hair growth, acne and difficulties with ovulation. He explained that PCOS is a complex hormonal and metabolic disorder, with excess weight representing only one aspect of the condition. Although weight reduction may improve metabolic health and menstrual regularity in some women, it does not necessarily resolve the underlying hormonal imbalance. Therefore, treatment should address individual symptoms and long-term health requirements rather than focus exclusively on the number on the weighing scale.
GLP-1 Medicines Require Careful Medical Assessment
GLP-1 receptor agonists help regulate appetite, increase feelings of fullness and control blood sugar levels. Depending on the medicine, doctors may prescribe them for type 2 diabetes or weight management in eligible patients. However, PCOS is not an established standalone indication for these medicines. The 2023 International Evidence-based Guideline for the Assessment and Management of PCOS states that doctors may consider anti-obesity medicines, including semaglutide and liraglutide, for adults with PCOS and higher body weight. However, treatment should follow general obesity-management guidelines and complement lifestyle interventions.
Dr Kunal Gupta, Consultant Endocrinologist at SPARSH Hospital, Infantry Road, Bengaluru, said doctors should assess body weight, blood glucose levels, insulin resistance and other associated risk factors before prescribing these medicines. He stressed that a PCOS diagnosis alone does not justify starting weight-loss injections. Instead, doctors must determine whether patients meet the criteria for pharmacological weight management and explain the potential benefits, side effects and available alternatives. Furthermore, these medicines should complement, rather than replace, appropriate nutrition, physical activity and regular medical follow-ups.
Weight Regain and Side Effects Require Attention
Experts also caution that patients may regain weight after discontinuing GLP-1 medicines because their appetite-suppressing effects diminish. The extent of weight regain varies between individuals. Dr Gupta advised patients to develop a long-term weight-management strategy with their doctors before stopping treatment. He emphasised that patients should not discontinue or restart injections independently. Similarly, Dr Nehal Dhaduk, Consultant Gynaecology at PB Health, Gurugram, highlighted the importance of counselling women about the possibility of weight regain before initiating treatment. She explained that these medicines are not a quick fix for PCOS. Instead, women should follow a sustainable management plan and maintain regular medical consultations to monitor their weight and metabolic health. Common side effects of GLP-1 medicines include nausea, vomiting, diarrhoea, constipation and abdominal discomfort. In some patients, more serious complications, such as gallbladder problems and pancreatitis, may also occur. Consequently, medical supervision remains essential to assess individual risks, select appropriate medicines and monitor treatment outcomes.
Pregnancy Planning Needs Special Consideration
Pregnancy planning is another important factor when considering weight-loss injections. Dr Megha Mittal, Senior Consultant, Obstetrics and Gynaecology, Apollo Spectra Hospital, Delhi, said improvements in metabolic health and ovulation may increase the chances of conception in some women with PCOS. However, women planning pregnancy must discuss their treatment with their doctors before starting GLP-1 medicines. These drugs should not be used for weight loss during pregnancy, and the recommended discontinuation period before conception varies depending on the medicine. For example, semaglutide should be discontinued at least two months before a planned pregnancy. Women should also discuss suitable contraception and preconception care with their gynaecologists. Dr Mittal further emphasised that PCOS management should address several aspects of women’s health, including menstrual regularity, fertility goals, mental well-being and metabolic risks such as type 2 diabetes.
Individualised Treatment Is Key to Long-Term PCOS Management
Depending on a woman’s symptoms and clinical assessment, doctors may recommend a combination of lifestyle modifications, hormonal contraceptives, metformin or fertility treatments. Experts emphasised that effective PCOS management requires a comprehensive, long-term approach. While weight-loss injections may benefit eligible women, they should form part of a medically supervised treatment strategy rather than serve as a standalone solution. As reported byptinews.com, uUltimately, the focus should remain on sustainable weight management, hormonal health and improved long-term well-being, rather than rapid weight loss through unsupervised medication.